Our company plays a vital role in pharmaceutical quality control through the research and development of culture media for mycoplasma exclusion testing. In response to the growing focus on regenerative medicine, we have significantly increased our investment in both liquid and agar media specifically designed for mycoplasma testing. Developing culture media capable of addressing microbiological challenges and enabling accurate and efficient mycoplasma detection is essential to ensuring safety in the pharmaceutical industry.
Moving forward, we will continue to focus on improving testing accuracy and developing higher-performance media, thereby further strengthening our reliability within the industry.
In addition, we are committed to driving technological innovation to ensure that our research outcomes are rapidly translated into practical applications in the market.